Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.

Co-located with our

REAL WORLD EVIDENCE SUMMIT

eyeforpharma Japan 2018 Commercial Excellence 11th Annual|May 16-17, 2018

Key topics to be covered:

Opening Keynote Session
XX:XX - XX:XX
Patient Engagement at a pharmaceutical company – Case studies at UCB Japan
  • History of “Patient Centricity” at UCB Japan
  • Evolution from “Patient Centricity” to “Patient Value Strategy” as UCB’s Global Strategy
  • Case studies at UCB Japan: a patient value mind-set at all levels of the organisation – current challenges and future

UCB Japan Co., Ltd. Satoshi Miki Japan Representative Director, Vice President, Head of CoE Strategy & Planning for East Asia Region UCB Japan Co., Ltd.

XX:XX - XX:XX
The Act on the Next-Generation Medical Infrastructure
  • To grasp the overview of "The Act on the Next-Generation Medical Infrastructure" promulgated for the realization of advanced and efficient medical care through the utilization of medical ICT.
  • To understand the impact of "The Act on the Next-Generation Medical Infrastructure" on research and business environment surrounding pharmaceutical companies.

Councillor, Cabinet Secretariat, Government of Japan Koji Fujimoto Deputy Director-General, Office of Healthcare Policy Councillor, Cabinet Secretariat, Government of Japan

XX:XX - XX:XX
Overcome pricing challenges: ensure your model demonstrates and communicates your true product value (Pharma perspective)
  • Prepare to show exactly how your product provides improved long-term value to the Japanese market in order to tackle the pricing challenges
  • Meet the requirements of upcoming healthcare policy, and find how you can help and support the Japanese healthcare system

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Thorsten Poehl President and Representative Director Boehringer Ingelheim Japan, Inc. Chairman and Representative Director Nippon Boehringer Ingelheim Co., Ltd.
Boehringer Ingelheim Animal Health Japan Co., Ltd.
Boehringer Ingelheim Seiyaku
Vice Chairman EFPIA-Japan

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Closing Keynote Session
XX:XX - XX:XX
Healthcare transformation through medical big data platform and future role of pharmaceutical companies
  • Introduce case examples on data collection and analysis of medical big data platform in Japan and the U.S.
  • Discuss future roles of pharma companies in community health transformation and R&D innovation for new drug development

PwC Consulting LLC Yujiro Tsutsumi Managing Executive Director
Health Industries Advisory
PwC Consulting LLC

XX:XX - XX:XX
Get your talent formula right: optimize for effective leadership
  • Improving the work environment to boost business performance Purpose, inclusion and innovation
  • The era of internal collaboration: enabling co-operation across functions
  • Reward and recognition in for today's organizations

Novartis David Lennon Oncology General Manager Japan Novartis

EYEFORPHARMA JAPAN 2018 SPECIAL - PRESIDENT / CEO PANEL DISCUSSION
XX:XX - XX:XX
Pharma as the primary partner for improving Japanese healthcare
  • How our companies can form a new relationship with stakeholders and work on shared objectives to create the ideal patient model
  • Examples from other countries where similar partnerships have provided win-win-win-win situations for pharma, government, HCP and patients
  • Visualizations of Japanese healthcare in 2020 & 2025: How is your workforce going to change?

Company_Name Satoru Noguchi President Celgene K.K.

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Stefan Woxström Representative Director and President AstraZeneca K.K.

Do you really know your customer?
Gain a deeper market understanding to predict customer behavior and determine where to add value
XX:XX - XX:XX
Reflect: Ignorance and prejudice towards patients" and "Learning: diversity of patients' values
  • Listen to patients' hope & expectation and distrust & dissatisfaction towards pharma
  • Listen to patients' voice and ask yourself if you are prioritising patient needs
  • Consider what information on medicine is necessary to patients

(JPPaC) Kazuyoshi Hatanaka President Japan Partners for Patient-Centric Care
(JPPaC)

DebRA Japan Keiko Miyamoto Representative Director DebRA Japan

General incorporated association  
Hokkaido Intractable Diseases Association (Nanbyo –ren) Yasuko Masuda Executive Director General incorporated association
Hokkaido Intractable Diseases Association (Nanbyo –ren)

XX:XX - XX:XX
Should patients be treated as "customers"? Consider pharma's social responsibility
  • Should pharmaceutical companies treat patients as their "customers"?
  • The presenter will discuss the appropriateness of adapting the concept of "customer creation" to patients in light of the patient narratives in
  • DIPEx (Database of Individual Patient Experiences)

DIPEx-Japan Rika Sakuma Sato Managing Director
Approved Specified Nonprofit Organization
DIPEx-Japan

XX:XX - XX:XX
Are you one of your doctor's trusted partners? Identify how doctors wish to communicate; then align with their preferences
  • How to analyze your doctor's thinking in order to access their prescription mentality and professional ambitions
  • Identify what pharma can do to support doctors in their quest for the right drug and right treatment for their patient
  • The new era of doctor expectations: how consumer brands have raised the bar for good service, and how you can achieve the right balance between online vs. face-to-face

Speaker to be revealed.

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Create a comprehensive database
Make better decisions and open more doors with more reliable customer data
XX:XX - XX:XX
Prediction of market share over time after launch using machine learning and real-world data, and its application
  • Introduce a theory of market share prediction using machine learning
  • Report results of back tests on example data of some launched products
  • Propose a method to design a PDCA cycle for marketing based on the share prediction

Milliman, Inc. Kosuke Iwasaki Director
Japan Healthcare Practice and Data Analytics
Milliman, Inc.

XX:XX - XX:XX
Put information on patient-centered decision support between doctor and patients into a database
  • Encourage Patient-centered decision making
  • Learn the measuring method of shared decision making
  • Understand the effect of decision aid and it's international standard

St. Luke's International University Kazuhiro Nakayama Professor
Graduate school of nursing science
St. Luke's International University

XX:XX - XX:XX
Challenges for seamless utilization of diverse data sources in Japan
  • Importance of master data management to manage the abundant HCP related data compared to other countries.
  • How do we suppose the psychographics of HCP by utilizing touch point data in the past?
  • Preparation of analytical data mart to accelerate our cross channel analytics.

GlaxoSmithKline K.K. Yoshihiko Nakajima Head
MC Data & System Management
GlaxoSmithKline K.K.

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Enhance customer engagement through digital innovation
XX:XX - XX:XX
Improve customer engagement through Artificial Intelligence: a practical guide to benefitting from this innovation
  • Learn from case studies: see how AI is already enabling better clinical decisions and the opportunities for your company
  • The timeline: look at progress to date and the likely future for this technology
  • How AI combined with other innovations will speed up organisational changes for commercial departments
  • Understand how to maintain high quality through clever use of AI

Speaker to be revealed.

XX:XX - XX:XX
From a traditional to a digital patient journey: how to understand, influence and support patients through social media and other tools
  • Not the same as other channels - appreciate the dynamics of online conversations in order to be considered genuine
  • Connect with patients in a meaningful way by helping them lower their overall health costs
  • Empower patients through self-management technologies and add value across the patient journey

Merck Ltd. Shinichiro Akaho Head of Business Technology Merck Ltd.

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

From mass-market to targeted
Improve your conversion rate with a more sophisticated approach
XX:XX - XX:XX
Marketing plan: is it just a show? A discussion on how it should be put into practice
  • Mass quantitative analysis moves your sales people?
  • What is customer "insight"?
  • Tips for "realistic" marketing plan

Pola Pharma Inc. Hiroshi Horikawa General Manager
Marketing Department
Pola Pharma Inc.

XX:XX - XX:XX
Make your rep messaging and marketing materials scientifically sound in order to ensure trust, safety, reliability and authenticity
  • Become your customer's trusted partner through greater solidarity with their medical aims
  • Maintain your company's credibility through delivering accurate and unified scientific messaging across the company
  • Deliver your message with proof of safety and efficacy to help your customer make a safe purchase decision

Speaker to be revealed.

XX:XX - XX:XX
Next generation targeted sales and marketing utilizing customer big data
  • Key data that should be accumulated by pharmaceutical companies
  • Big data based optimization of resource allocations and of detail customization per physician
  • Digitalization of MR activities to facilitate big data accumulation and utilization, and the future of sales and marketing

M3, Inc. Yoichi Katayama Senior Director
Solution Partner Business Unit
M3, Inc.

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Introduce smarter thinking into your sales force: go beyond simple sales techniques so that MRs become the customer representatives of the future
XX:XX - XX:XX
A focus on niche/speciality care sales techniques - understand how MRs should adapt
  • Shift towards' niche/speciality products which could potentially yield good profits
  • Create a personalized approach with a deeper understanding of your customer and a more sophisticated model

Aegerion Pharmaceuticals K.K. Masako Nakamura President, Representative Director Aegerion Pharmaceuticals K.K.

XX:XX - XX:XX
Build smarter thinking into your sales force: go beyond the usual MR model and think how it should change
  • Evaluate what should stay the same and should change, looking to current trends and future.
  • As the external environment becomes ever so complicated, how can the field staff and head office communicate well
  • Future tasks to optimize human productivity

Gilead Sciences K.K. Tomoo Miyake Associate Director
Sales Promotion/Learning Development Dept.
Gilead Sciences K.K.

XX:XX - XX:XX
Determine whether sales skills are the defining factor in the future MR - and whether certain parts of the role should now be automated for order to focus elsewhere
  • Enough discussion; let's clarify where to allocate your resources effectively for our new landscape
  • How to determine the right ratio of MRs for your company depending on capabilities required
  • Your 2020 vision: Which it be the same path for everyone, or are your requirements unique?

Aegerion Pharmaceuticals K.K. Masako Nakamura President, Representative Director Aegerion Pharmaceuticals K.K.

Gilead Sciences K.K. Tomoo Miyake Associate Director
Sales Promotion/Learning Development Dept.
Gilead Sciences K.K.

The Nielsen Company Japan Kazuhiro Miyatsu Executive Director
Marketing Science Analytics & Consulting
The Nielsen Company Japan


More speakers to be revealed.

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Successfully execute your commercial strategy: Manage a forward looking transition
XX:XX - XX:XX
Walk before you run: how to map community-based healthcare and plan the best organizational structure
  • Identify how you can adapt to the different role of each stakeholder from this point onwards
  • Spot the vital signs in order to keep your ear close to market shifts
  • How to position your teams as strategic partners in improving Japanese healthcare

Toho Holdings Co., Ltd. Hiroshi Ito General Manager
Regional Medical Cooperation Department
Toho Holdings Co., Ltd.

XX:XX - XX:XX
Make the right investments for commercial innovation: Deliver value through reliable data insight and digital intervention
  • Overcoming challenges in Japan’s healthcare system, including innovation adoption, pricing, care and aging society by focusing on value and providing holistic solutions
  • Realizing meaningful customer experiences through data, digital and technology, global and local approaches
  • Partnering for long-term value in the Japanese healthcare system – what is pharma role?

Novartis David Lennon Oncology General Manager Japan Novartis

Opening Keynote Session
XX:XX - XX:XX
Patient Engagement at a pharmaceutical company – Case studies at UCB Japan
  • History of “Patient Centricity” at UCB Japan
  • Evolution from “Patient Centricity” to “Patient Value Strategy” as UCB’s Global Strategy
  • Case studies at UCB Japan: a patient value mind-set at all levels of the organisation – current challenges and future

UCB Japan Co., Ltd. Satoshi Miki Japan Representative Director, Vice President, Head of CoE Strategy & Planning for East Asia Region UCB Japan Co., Ltd.

XX:XX - XX:XX
The Act on the Next-Generation Medical Infrastructure
  • To grasp the overview of "The Act on the Next-Generation Medical Infrastructure" promulgated for the realization of advanced and efficient medical care through the utilization of medical ICT.
  • To understand the impact of "The Act on the Next-Generation Medical Infrastructure" on research and business environment surrounding pharmaceutical companies.

Councillor, Cabinet Secretariat, Government of Japan Koji Fujimoto Deputy Director-General, Office of Healthcare Policy Councillor, Cabinet Secretariat, Government of Japan

XX:XX - XX:XX
Overcome pricing challenges: ensure your model demonstrates and communicates your true product value (Pharma perspective)
  • Prepare to show exactly how your product provides improved long-term value to the Japanese market in order to tackle the pricing challenges
  • Meet the requirements of upcoming healthcare policy, and find how you can help and support the Japanese healthcare system

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Thorsten Poehl President and Representative Director Boehringer Ingelheim Japan, Inc. Chairman and Representative Director Nippon Boehringer Ingelheim Co., Ltd.
Boehringer Ingelheim Animal Health Japan Co., Ltd.
Boehringer Ingelheim Seiyaku
Vice Chairman EFPIA-Japan

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Do you really know your customer?
Gain a deeper market understanding to predict customer behavior and determine where to add value
XX:XX - XX:XX
Reflect: Ignorance and prejudice towards patients" and "Learning: diversity of patients' values
  • Listen to patients' hope & expectation and distrust & dissatisfaction towards pharma
  • Listen to patients' voice and ask yourself if you are prioritising patient needs
  • Consider what information on medicine is necessary to patients

(JPPaC) Kazuyoshi Hatanaka President Japan Partners for Patient-Centric Care
(JPPaC)

DebRA Japan Keiko Miyamoto Representative Director DebRA Japan

General incorporated association  
Hokkaido Intractable Diseases Association (Nanbyo –ren) Yasuko Masuda Executive Director General incorporated association
Hokkaido Intractable Diseases Association (Nanbyo –ren)

XX:XX - XX:XX
Should patients be treated as "customers"? Consider pharma's social responsibility
  • Should pharmaceutical companies treat patients as their "customers"?
  • The presenter will discuss the appropriateness of adapting the concept of "customer creation" to patients in light of the patient narratives in
  • DIPEx (Database of Individual Patient Experiences)

DIPEx-Japan Rika Sakuma Sato Managing Director
Approved Specified Nonprofit Organization
DIPEx-Japan

XX:XX - XX:XX
Are you one of your doctor's trusted partners? Identify how doctors wish to communicate; then align with their preferences
  • How to analyze your doctor's thinking in order to access their prescription mentality and professional ambitions
  • Identify what pharma can do to support doctors in their quest for the right drug and right treatment for their patient
  • The new era of doctor expectations: how consumer brands have raised the bar for good service, and how you can achieve the right balance between online vs. face-to-face

Speaker to be revealed.

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Create a comprehensive database
Make better decisions and open more doors with more reliable customer data
XX:XX - XX:XX
Prediction of market share over time after launch using machine learning and real-world data, and its application
  • Introduce a theory of market share prediction using machine learning
  • Report results of back tests on example data of some launched products
  • Propose a method to design a PDCA cycle for marketing based on the share prediction

Milliman, Inc. Kosuke Iwasaki Director
Japan Healthcare Practice and Data Analytics
Milliman, Inc.

XX:XX - XX:XX
Put information on patient-centered decision support between doctor and patients into a database
  • Encourage Patient-centered decision making
  • Learn the measuring method of shared decision making
  • Understand the effect of decision aid and it's international standard

St. Luke's International University Kazuhiro Nakayama Professor
Graduate school of nursing science
St. Luke's International University

XX:XX - XX:XX
Challenges for seamless utilization of diverse data sources in Japan
  • Importance of master data management to manage the abundant HCP related data compared to other countries.
  • How do we suppose the psychographics of HCP by utilizing touch point data in the past?
  • Preparation of analytical data mart to accelerate our cross channel analytics.

GlaxoSmithKline K.K. Yoshihiko Nakajima Head
MC Data & System Management
GlaxoSmithKline K.K.

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Enhance customer engagement through digital innovation
XX:XX - XX:XX
Improve customer engagement through Artificial Intelligence: a practical guide to benefitting from this innovation
  • Learn from case studies: see how AI is already enabling better clinical decisions and the opportunities for your company
  • The timeline: look at progress to date and the likely future for this technology
  • How AI combined with other innovations will speed up organisational changes for commercial departments
  • Understand how to maintain high quality through clever use of AI

Speaker to be revealed.

XX:XX - XX:XX
From a traditional to a digital patient journey: how to understand, influence and support patients through social media and other tools
  • Not the same as other channels - appreciate the dynamics of online conversations in order to be considered genuine
  • Connect with patients in a meaningful way by helping them lower their overall health costs
  • Empower patients through self-management technologies and add value across the patient journey

Merck Ltd. Shinichiro Akaho Head of Business Technology Merck Ltd.

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

From mass-market to targeted
Improve your conversion rate with a more sophisticated approach
XX:XX - XX:XX
Marketing plan: is it just a show? A discussion on how it should be put into practice
  • Mass quantitative analysis moves your sales people?
  • What is customer "insight"?
  • Tips for "realistic" marketing plan

Pola Pharma Inc. Hiroshi Horikawa General Manager
Marketing Department
Pola Pharma Inc.

XX:XX - XX:XX
Make your rep messaging and marketing materials scientifically sound in order to ensure trust, safety, reliability and authenticity
  • Become your customer's trusted partner through greater solidarity with their medical aims
  • Maintain your company's credibility through delivering accurate and unified scientific messaging across the company
  • Deliver your message with proof of safety and efficacy to help your customer make a safe purchase decision

Speaker to be revealed.

XX:XX - XX:XX
Next generation targeted sales and marketing utilizing customer big data
  • Key data that should be accumulated by pharmaceutical companies
  • Big data based optimization of resource allocations and of detail customization per physician
  • Digitalization of MR activities to facilitate big data accumulation and utilization, and the future of sales and marketing

M3, Inc. Yoichi Katayama Senior Director
Solution Partner Business Unit
M3, Inc.

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Introduce smarter thinking into your sales force: go beyond simple sales techniques so that MRs become the customer representatives of the future
XX:XX - XX:XX
A focus on niche/speciality care sales techniques - understand how MRs should adapt
  • Shift towards' niche/speciality products which could potentially yield good profits
  • Create a personalized approach with a deeper understanding of your customer and a more sophisticated model

Aegerion Pharmaceuticals K.K. Masako Nakamura President, Representative Director Aegerion Pharmaceuticals K.K.

XX:XX - XX:XX
Build smarter thinking into your sales force: go beyond the usual MR model and think how it should change
  • Evaluate what should stay the same and should change, looking to current trends and future.
  • As the external environment becomes ever so complicated, how can the field staff and head office communicate well
  • Future tasks to optimize human productivity

Gilead Sciences K.K. Tomoo Miyake Associate Director
Sales Promotion/Learning Development Dept.
Gilead Sciences K.K.

XX:XX - XX:XX
Determine whether sales skills are the defining factor in the future MR - and whether certain parts of the role should now be automated for order to focus elsewhere
  • Enough discussion; let's clarify where to allocate your resources effectively for our new landscape
  • How to determine the right ratio of MRs for your company depending on capabilities required
  • Your 2020 vision: Which it be the same path for everyone, or are your requirements unique?

Aegerion Pharmaceuticals K.K. Masako Nakamura President, Representative Director Aegerion Pharmaceuticals K.K.

Gilead Sciences K.K. Tomoo Miyake Associate Director
Sales Promotion/Learning Development Dept.
Gilead Sciences K.K.

The Nielsen Company Japan Kazuhiro Miyatsu Executive Director
Marketing Science Analytics & Consulting
The Nielsen Company Japan


More speakers to be revealed.

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Successfully execute your commercial strategy: Manage a forward looking transition
XX:XX - XX:XX
Walk before you run: how to map community-based healthcare and plan the best organizational structure
  • Identify how you can adapt to the different role of each stakeholder from this point onwards
  • Spot the vital signs in order to keep your ear close to market shifts
  • How to position your teams as strategic partners in improving Japanese healthcare

Toho Holdings Co., Ltd. Hiroshi Ito General Manager
Regional Medical Cooperation Department
Toho Holdings Co., Ltd.

XX:XX - XX:XX
Make the right investments for commercial innovation: Deliver value through reliable data insight and digital intervention
  • Overcoming challenges in Japan’s healthcare system, including innovation adoption, pricing, care and aging society by focusing on value and providing holistic solutions
  • Realizing meaningful customer experiences through data, digital and technology, global and local approaches
  • Partnering for long-term value in the Japanese healthcare system – what is pharma role?

Novartis David Lennon Oncology General Manager Japan Novartis

Register Now

There are only a limited number of passes left - Secure your place to this sell out event!

Closing Keynote Session
XX:XX - XX:XX
Healthcare transformation through medical big data platform and future role of pharmaceutical companies
  • Introduce case examples on data collection and analysis of medical big data platform in Japan and the U.S.
  • Discuss future roles of pharma companies in community health transformation and R&D innovation for new drug development

PwC Consulting LLC Yujiro Tsutsumi Managing Executive Director
Health Industries Advisory
PwC Consulting LLC

XX:XX - XX:XX
Get your talent formula right: optimize for effective leadership
  • Improving the work environment to boost business performance Purpose, inclusion and innovation
  • The era of internal collaboration: enabling co-operation across functions
  • Reward and recognition in for today's organizations

Novartis David Lennon Oncology General Manager Japan Novartis

EYEFORPHARMA JAPAN 2018 SPECIAL - PRESIDENT / CEO PANEL DISCUSSION
XX:XX - XX:XX
Pharma as the primary partner for improving Japanese healthcare
  • How our companies can form a new relationship with stakeholders and work on shared objectives to create the ideal patient model
  • Examples from other countries where similar partnerships have provided win-win-win-win situations for pharma, government, HCP and patients
  • Visualizations of Japanese healthcare in 2020 & 2025: How is your workforce going to change?

Company_Name Satoru Noguchi President Celgene K.K.

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Stefan Woxström Representative Director and President AstraZeneca K.K.

Don't miss out - register now

There are only a limited number of passes left - Secure your place to this sell out event!